OTC · Medical - Pharmaceuticals

Camurus AB (CAMRF) Stock

$58.51 +0.00% OTC: CAMRF Healthcare

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines.

Valuation

MetricValue
Price$58.51
Market Cap$3.48B
P/E Ratio53.29
P/B Ratio7.72
P/S Ratio15.94
EPS (TTM)$1.10
52-Week High$71.00
52-Week Low$54.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE15.54%
ROA12.78%
ROCE17.10%
Gross Margin92.49%
Operating Margin36.33%
Net Margin29.92%
Debt/Equity0.02
Current Ratio10.01

Annual Financials (USD)

Metric20212022202320242025
Revenue$601.0M$956.0M$1.7B$1.9B$2.3B
Operating Profit$-111.0M$72.0M$526.0M$469.0M$874.0M
Net Profit$-90.0M$56.0M$431.0M$428.0M$736.0M
EPS$-1.66$1.01$7.50$7.20$12.26
Op Margin-18.4%7.5%30.6%25.1%38.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$1.3B$1.9B$3.8B$4.7B
Total Liabilities$233.0M$311.0M$415.0M$467.0M$505.0M
Cash$412.0M$566.0M$1.2B$2.9B$3.7B
Borrowings$26.0M$26.0M$25.0M$17.0M$106.0M

Latest News

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA PR Newswire · Jul 17, 2026 Camurus AB (CAMRF) Q2 2026 Earnings Call Highlights: Record Sales and Strategic Challenges GuruFocus.com · Jul 15, 2026 Camurus announces expansion of Lilly collaboration PR Newswire · Jun 1, 2026 Assessing Camurus (OM:CAMX) Valuation After Mixed Recent Share Performance Simply Wall St. · May 29, 2026 [Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-143.0M$101.0M$607.0M$390.0M$869.0M
Investing Cash Flow$-10.0M$3.0M$-20.0M$-59.0M$-277.0M
Financing Cash Flow$-7.0M$-15.0M$-4.0M$0$-18.0M
Net Cash Flow$-50.0M$154.0M$624.0M$1.7B$873.0M
Free Cash Flow$-148.0M$99.0M$597.0M$360.0M$731.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-7.94
EV / EBITDA36.35
FCF Yield1.81%
Quick Ratio9.70
Interest Coverage139.68
Return 1Y-17.59%
Return 3Y168.27%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKBLFALK-Abelló A/S $37.92 +0.00% 40.69 $7.63B 0.63%
AMBBYAmbu A/S $10.86 +0.00% 41.15 $2.89B 0.55%
GLPGFLakefront Biotherapeutics $28.08 +0.00% 3.47 $1.85B 0.00%
GNNSFGenscript Biotech Corporation $3.08 +5.12% -12.23 $6.73B 0.00%
INCPFInnoCare Pharma Limited $1.55 +0.00% 31.80 $2.32B 0.00%

About Camurus AB

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Camurus AB is headquartered in SE.

Camurus AB (CAMRF) stock trades at $58.51 with a market capitalization of $3.48B. The stock is valued at a price-to-earnings (P/E) ratio of 53.29, price-to-book of 7.72, price-to-sales of 15.94. Over the past 52 weeks the stock has ranged between $54.00 and $71.00, and currently trades 17.6% below its 52-week high.

On profitability, Camurus AB generates a return on equity (ROE) of 15.54%, above the typical market average, return on capital employed of 17.10%, an operating margin of 36.33%, a net profit margin of 29.92%.

Official website: www.camurus.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides